Proliferation-attenuating and apoptosis-inducing effects of tryptanthrin on human chronic myeloid leukemia K562 cell

Shan Miao1, Xiaopeng Shi, Hai Zhang

  • 1Institute of Materia Medica, School of Pharmacy, Fourth Military Medical University, #17 West Changle Road, Xi'an 710032, China; E-Mails: miaoshan@fmmu.edu.cn (S.M.); sunjiy@fmmu.edu.cn (J.S.); miaoqing@fmmu.edu.cn (Q.M.).

Insights

Tryptanthrin significantly inhibits chronic myeloid leukemia K562 cell proliferation and induces apoptosis. This indole alkaloid affects mitochondrial membrane potential and caspase activation, offering potential therapeutic avenues.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Background:

  • Tryptanthrin, an indole quinazoline alkaloid, possesses known antimicrobial, anti-inflammatory, and antitumor properties.
  • The specific effects of tryptanthrin on human chronic myeloid leukemia (CML) K562 cells remain incompletely characterized.

Purpose of the Study:

  • To investigate the antiproliferative and apoptosis-inducing effects of tryptanthrin on K562 cells.
  • To elucidate the underlying molecular mechanisms of tryptanthrin's action on leukemia cells.

Main Methods:

  • MTT assay and flow cytometry were used to assess cell proliferation and apoptosis.
  • Electron microscopy and Hoechst 33258 staining were employed to observe morphological changes.
  • Mitochondrial membrane potential, cytochrome c release, and caspase activation (caspase-3) were analyzed.

Main Results:

  • Tryptanthrin demonstrated significant, time- and dose-dependent inhibition of K562 cell proliferation.
  • Morphological analysis revealed apoptosis, including pyknosis and apoptotic body formation.
  • Tryptanthrin induced a decrease in mitochondrial membrane potential, increased cytosolic cytochrome c, and promoted caspase-3 activation, which was reversible with a caspase inhibitor.

Conclusions:

  • Tryptanthrin exhibits significant proliferation-attenuating and apoptosis-inducing effects on K562 leukemia cells.
  • The mechanism involves mitochondrial dysfunction, cytochrome c release, and caspase-3 activation.
  • Tryptanthrin shows potential as a therapeutic agent against chronic myeloid leukemia.